

Appendix A: pCODR Clinician Conf	lict of Interest Declarations
Please note: Each registered clinician must con emplate even if the submission is made jointly	mplete their own separate pCODR Clinician Conflict of Interest Declarations y.
Name of registered clinician:	Sebastien Hotte
Name of drug and indication under review:	avelumab
Conflict of Interest Declaration	
onflicts of interest. A registered clinician must dec	ODR process, all participants in the pCODR review process must disclose any clare any potential conflicts of interest that may influence or have the appearance of interest declaration is requested for transparency — it does not negate or
xamples of conflicts of interest include, but are no	ot limited to:
gifts, and salary)	stry or other entities (e.g., educational or research grants, honoraria, hips with drug manufacturers or other interest groups.
Section A: Payment Received	
•	evious two years from any company or organization that may have a direct or
⊠ Yes □ No	
If no, please go to Section B.	
. What form of payment did you receive? (Chec	k all that apply.)
Advisory role (e.g., advisory boards, heatechnology assessment submission adv	
☐ Conference attendance	⊠ Research/educational grants
□ D#:	☐ Travel grants
☐ Royalties	
☐ Royalties	☐ Sponsorship of events



Company	Nature or description of activities or interests	Check Appropriate Dollar Range			
		\$0 to 5,000	\$5,001 to 10,000	\$10,001 to 50,000	In Excess of \$50,000
Pfizer (avelumab)	Advisory board meetings	\boxtimes			
Merck (pembrolizumab) Research (institution); Advisory board meetings		\boxtimes			

Section B: Holdings or Other Interests

H	lave you received or are in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that
n	nay have a direct or indirect interest in the drug under review? If yes, please list them in the following box.

No.		

Section C: Affiliations, Personal or Commercial Relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including the manufacturer's parent corporation, subsidiaries, affiliates, and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations, and outline the nature of these relationships, in the following box.

No.	
By checking this box, I hereby certify that the information that I have presented here is accurate and complete to the best of my knowledge.	

2020/08/26	
Date	



Appendix A: pCODR Clinician Conflict of Interest Declarations

Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician:		Dr. Aly-Khan Lalani			
N	Name of drug and indication under review:	pCODR 10225 – avelumab for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with first-line platinum-based induction chemotherapy.			
Со	nflict of Interest Declaration				
con of ir	flicts of interest. A registered clinician must decl	DDR process, all participants in the pCODR review process must disclose any are any potential conflicts of interest that may influence or have the appearance of interest declaration is requested for transparency — it does not negate or			
Ξха	amples of conflicts of interest include, but are no	t limited to:			
•	gifts, and salary)	try or other entities (e.g., educational or research grants, honoraria, ips with drug manufacturers or other interest groups.			
эе (•				
1.	Have you received any payments over the pre- indirect interest in the drug under review?	vious two years from any company or organization that may have a direct or			
	⊠ Yes □ No				
	If no, please go to Section B.				
2.	What form of payment did you receive? (Check	c all that apply.)			
	☑ Advisory role (e.g., advisory boards, heat technology assessment submission adv	·			
	☐ Conference attendance	☐ Research/educational grants			
	☐ Royalties	☐ Travel grants			
	☐ Gifts	☐ Sponsorship of events			
		☐ Other, please specify:			

3. Please provide the names of companies and organizations, and the amounts of the payments, in the following table.

Company	Nature or description of activities or interests	Check Appropriate Dollar Range			
			\$5,001 to 10,000	\$10,001 to 50,000	In Excess of \$50,000
Pfizer	Honoraria/advisory	\boxtimes			



			Ш	
Section B: Holdings or Other Interests				
Have you received or are in possession of stocks or options of mo	ore than \$10,000 (excludir	ng mutual funds)	for organizat	tions that
may have a direct or indirect interest in the drug under review? If y	es, please list them in the	e following box.		
NO				
Section C: Affiliations, Personal or Commercial Relatio	nships			
Do you have personal or commercial relationships either with a dr	-	nanufacturer (inc	ludina the m	anufacturer's
parent corporation, subsidiaries, affiliates, and associated corpora	itions) or other interest gre	oups? If yes, plea		
the companies and organizations, and outline the nature of these	relationships, in the follow	ving box.		
NO				
NO				
By checking this box, I hereby certify that the information that I h	ave presented here is		\boxtimes	
accurate and complete to the best of my knowledge.				
September 25, 2020				
Date				